NEW YORK (GenomeWeb) – Qiagen Translational Medicine Research in Suzhou, China (Qiagen Suzhou), has completed a Series A financing for RMB 175 million ($25.7 million).

Chinese venture capital firm Qiming Venture Partners led the round, with participation from New Horizon Capital, Quanchuang Capital, and Shanghai Anjie Medical Equipment Company, according to a report from China Money Network.